QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse eventsQR-421a is the second ophthalmology program where clinical activity was predicted by tra
… ProQR Receives Orphan Drug Designation from FDA for Drug … Present Data at two Scientific Conferences Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis … David M. Rodman, MD, Chief Development Strategy Officer of ProQR, “It highlights the unmet need in this devastating …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … molecule that will move into clinical development using ProQR’s RNA approach. ARVO The p.Cys998X mutation which is a …
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course
QR-110 was well-tolerated with no serious adverse events